Sagent Pharmaceuticals (SGNT) Tops Q3 EPS by 10c; Guides FY14 Revs Below Views

Sagent Pharmaceuticals (NASDAQ: SGNT) reported Q3 EPS of $0.06, $0.10 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $65.4 million versus the consensus estimate of $64.01 million.

Sagent Pharmaceuticals sees FY2014 revenue of $275-285 million, versus the consensus of $287.8 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• The First Of Long Island (FLIC) Misses Q1 EPS by 3c
• COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance